Genomic biomarkers for cardiotoxicity in rats as a sensitive tool in preclinical studies

Journal of Applied Toxicology

Volumn 33, Issue 10, 2013, Pages 1120-1130

  Nishimura, Yoko ^a   Morikawa, Yuji ^a   Kondo, Chiaki ^a   Tonomura, Yutaka ^a   Fukushima, Ryou ^a   Torii, Mikinori ^a   Uehara, Takeki ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Cardiac troponin; Cardiotoxicity; Drug development; Genomic biomarker; Toxicogenomics

Indexed keywords

ALLYL ALCOHOL; ALLYLAMINE; BIOLOGICAL MARKER; BRANCHED CHAIN AMINOTRANSFERASE 1; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; FOUR AND A HALF LIM DOMAIN PROTEIN 1; ISOPRENALINE; LIM AND CYSTEINE RICH DOMAIN 1; MITOXANTRONE; ORCIPRENALINE; OSTEOPONTIN; RESERPINE; SERPINE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA2; TROPONIN I; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMICS; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUPPORT VECTOR MACHINE; UPREGULATION;

RATTUS;

EID: 84880928534     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2867     Document Type: Article

References (65)

1. Achudume AC, Ogunyemi KE. 2007. Effects of the extracts of Pycanthus angolensis against chemically induced acute hepatotoxicity. Pak. J. Biol. Sci. 15: 3231-3233.
2. Amin P, Singh M, Singh K. 2011. β-Adrenergic Receptor-Stimulated Cardiac Myocyte Apoptosis: Role of β1 Integrins. J. Signal Transduct. Epub., 2011: 179057.
3. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. 2000. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 60: 1789-1792.
4. Balazs T, Ferrans VJ. 1978. Cardiac lesions induced by chemicals. Environ. Health Perspec. 26: 181-191.
5. Barton PJ, Birks EJ, Felkin LE, Cullen ME, Koban MU, Yacoub MH. 2003. Increased expression of extracellular matrix regulators TIMP1 and MMP1 in deteriorating heart failure. J. Heart Lung Transplant. 22: 738-744.
6. Bian ZY, Huang H, Jiang H, Shen DF, Yan L, Zhu LH, Wang L, Cao F, Liu C, Tang QZ, Li H. 2010. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling. Hypertension 55: 257-263.
7. Bledsoe RK, Dawson PA, Hutson SM. 1997. Cloning of the rat and human mitochondrial branched chain aminotransferases (BCATm). Biochim. Biophys. Acta 1339: 9-13.
8. Boyd JW. 1988. Serum enzymes in the diagnosis of disease in man and animals. J. Comp. Pathol. 98: 381-404.
9. Briest W, Homagk L, Rassler B, Ziegelhöffer-Mihalovicová B, Meier H, Tannapfel A, Leiblein S, Saalbach A, Deten A, Zimmer HG. 2004. Norepinephrine-induced changes in cardiac transforming growth factor-beta isoform expression pattern of female and male rats. Hypertension 44: 410-418.
10. Broder H, Gottlieb RA, Lepor NE. 2008. Chemotherapy and cardiotoxicity. Rev. Cardiovasc. Med. 9: 75-83.
11. Cao HX, Sun H, Jiang XG, Lu HT, Zhang GM, Wang XJ, Sun WJ, Wu ZM, Wang P, Liu L, Zhou J. 2009. Comparative study on the protective effects of Yinchenhao Decoction against liver injury induced by alpha-naphthylisothiocyanate and carbon tetrachloride. Chin. J. Integr. Med. 15: 204-209.
12. Caulfield JB, Borg TK. 1979. The collagen network of the heart. Lab. Invest. 40: 364-372.
13. Chardin P. 2006. Function and regulation of Rnd proteins. Nat. Rev. Mol. Cell Biol. 7: 54-62.
14. Chen FS, Ito H, Okabe F, Momose Y, Yamamura S, Ridtitid W, Chaichantipyuth C, Leelasangaluk V, Tongroach P. 1999. Effects of barakol on aconitine-induced cardiac arrhythmias. Pharm. Biol. 37: 105-108.
15. Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB. 2007. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc. Toxicol. 7: 114-121.
16. Chu PH, Ruiz-Lozano P, Zhou Q, Cai C, Chen J. 2000. Expression patterns of FHL/SLIM family members suggest important functional roles in skeletal muscle and cardiovascular system. Mech. Dev. 95: 259-265.
17. Conklin DJ, Boor PJ. 1998. Allylamine cardiovascular toxicity: evidence for aberrant vasoreactivity in rats. Toxicol. Appl. Pharmacol. 148: 245-251.
18. Eden A, Benvenisty N. 1999. Involvement of branched-chain amino acid aminotransferase (Bcat1/Eca39) in apoptosis. FEBS Lett. 457: 255-261.
19. El-Shenawy NS, Abdel-Rahman MS. 1993. Evaluation of chloroform cardiotoxicity utilizing a modified isolated rat cardiac myocytes. Toxicol. Lett. 69: 249-256.
20. Fabre N, Anglade I, Vericat JA. 2009. Application of toxicogenomic tools in the drug research and development process. Toxicol. Lett. 186: 13-17.
21. Fairley KF, Woo KT, Birch DF, Leaker BR, Ratnaike S. 1986. Triamterene-induced crystalluria and cylinduria: clinical and experimental studies. Clin. Nephrol. 26: 169-173.
22. Frank D, Frauen R, Hanselmann C, Kuhn C, Will R, Gantenberg J, Füzesi L, Katus HA, Frey N. 2010. Lmcd1/Dyxin, a novel Z-disc associated LIM protein, mediates cardiac hypertrophy in vitro and in vivo. J. Mol. Cell. Cardiol. 49: 673-682.
23. Fung M, Thornton A, Mybeck K, Hsiao-Hui W, Hornbuckle K, Muniz E. 2001. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Info. J. 35: 293-317.
24. Gaussin V, Tomlinson JE, Depre C, Engelhardt S, Antos CL, Takagi G, Hein L, Topper JN, Liggett SB, Olson EN, Lohse MJ, Vatner SF, Vatner DE. 2003. Common genomic response in different mouse models of beta-adrenergic-induced cardiomyopathy. Circulation 108: 2926-2933.
25. Ge F, He QY. 2009. Genomic and proteomic approaches for predicting toxicity and adverse drug reactions. Expert Opin. Drug Metab. Toxicol. 5: 29-37.
26. Ghosh AK, Bradham WS, Gleaves LA, De Taeye B, Murphy SB, Covington JW, Vaughan DE. 2010. Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice: involvement of constitutive transforming growth factor-beta signaling and endothelial-to-mesenchymal transition. Circulation 122: 1200-1209.
27. Graham HK, Horn M, Trafford AW. 2008. Extracellular matrix profiles in the progression to heart failure. Acta Physiol. (Oxford) 194: 3-21.
28. Herman EH, Zhang J, Hasinoff BB, Clark JR, Jr, Ferrans VJ. 1997. Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J. Mol. Cell. Cardiol. 29: 2415-2430.
29. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P, Van De Werf F, Pinto YM, Janssens S. 2005. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 112: 1136-1144.
30. Jin SM, Kil HR, Park K, Noh CI. 2012. Gene expression in rat hearts following oral administration of a single hepatotoxic dose of acetaminophen. Yonsei Med. J. 53: 172-180.
31. Kelishomi RB, Ejtemaeemehr S, Tavangar SM, Rahimian R, Mobarakeh JI, Dehpour AR. 2008. Morphine is protective against doxorubicin-induced cardiotoxicity in rat. Toxicology 243: 96-104.
32. Komatsubara I, Murakami T, Kusachi S, Nakamura K, Hirohata S, Hayashi J, Takemoto S, Suezawa C, Ninomiya Y, Shiratori Y. 2003. Spatially and temporally different expression of osteonectin and osteopontin in the infarct zone of experimentally induced myocardial infarction in rats. Cardiovasc. Pathol. 12: 186-194.
33. Koporec KP, Kim HJ, MacKenzie WF, Bruckner JV. 1995. Effect of oral dosing vehicles on the subchronic hepatotoxicity of carbon tetrachloride in the rat. J. Toxicol. Environ. Health 44: 13-27.
34. Korff S, Katus HA, Giannitsis E. 2006. Differential diagnosis of elevated troponins. Heart 92: 987-993.
35. Lenga Y, Koh A, Perera AS, McCulloch CA, Sodek J, Zohar R. 2007. Osteopontin Expression Is Required for Myofibroblast Differentiation. Circ. Res. 102: 319-327.
36. Lim DS, Roberts R, Marian AJ. 2001. Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. J. Am. Coll. Cardiol. 38: 1175-1180.
37. Loeb WF, Quimby Fred W. 1999. Clinical Chemistry of Laboratory Animals. Taylor and Francis: Philadelphia, PA, USA.
38. Lukashev ME, Werb Z. 1998. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 8: 437-441.
39. Mettler FP, Young DM, Ward JM. 1977. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res. 37: 2705-2713.
40. Mori Y, Kondo C, Tonomura Y, Torii M, Uehara T. 2010. Identification of potential genomic biomarkers for early detection of chemically induced cardiotoxicity in rats. Toxicology 271: 36-44.
41. Mori Y, Izawa T, Takenaka S, Kuwamura M, Yamate J. 2009. Participation of functionally different macrophage populations and monocyte chemoattractant protein-1 in early stages of thioacetamide-induced rat hepatic injury. Toxicol. Pathol. 37: 463-473.
42. Motlik K, Marek J, Starka L. 1977. Influence of single peroral dose of aminoglutethimide on the rat adrenal cortex. Endocrinol. Exp. 11: 285-297.
43. National Toxicology Program. 1989. NTP Toxicology and Carcinogenesis Studies of Nitrofurantoin (CAS No. 67-20-9) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl. Toxicol. Program Tech. Rep. Ser. 341: 1-218.
44. Nobes CD, Lauritzen I, Mattei MG, Paris S, Hall A, Chardin P. 1998. A new member of the Rho family, Rnd1, promotes disassembly of actin filament structures and loss of cell adhesion. J. Cell Biol. 141: 187-197.
45. O'Brien PJ. 2008. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology 245: 206-218.
46. Oliveira PJ, Rolo AP, Seiça R, Santos MS, Palmeira CM, Moreno AJ. 2003. Reduction in cardiac mitochondrial calcium loading capacity is observable during alpha-naphthylisothiocyanate-induced acute cholestasis: a clue for hepatic-derived cardiomyopathies? Biochim. Biophys. Acta 1637: 39-45.
47. Owen RA, Heywood R. 1986. Strain-related susceptibility to nephrotoxicity induced by aspirin and phenylbutazone in rats. Toxicol. Pathol. 14: 242-246.
48. Peterson JT, Li H, Dillon L, Bryant JW. 2000. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc. Res. 46: 307-315.
49. Price SA, Davies D, Rowlinson R, Copley CG, Roche A, Falkenberg FW, Riccardi D, Betton GR. 2010. Characterization of renal papillary antigen 1 (RPA-1), a biomarker of renal papillary necrosis. Toxicol. Pathol. 38: 346-358.
50. Reagan WJ. 2010. Troponin as a biomarker of cardiac toxicity: past, present, and future. Toxicol. Pathol. 38: 1134-1137.
51. Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, Hiramori K. 2005. Myocardial osteopontin expression is associated with collagen fibrillogenesis in human dilated cardiomyopathy. Eur. J. Heart Fail. 7: 755-762.
52. Selcoki Y, Uz E, Bayrak R, Sahin S, Kaya A, Uz, B, Karanfil A, Ozkara A, Akcay A. 2007. The protective effect of erdosteine against cyclosporine A-induced cardiotoxicity in rats. Toxicology 239: 53-59.
53. Senthilkumar S, Devaki T, Manohar BM, Babu MS. 2006. Effect of squalene on cyclophosphamide-induced toxicity. Clin. Chim. Acta 364: 335-342.
54. Sklar JL, Anderson PG, Boor PJ. 1991. Allylamine and acrolein toxicity in perfused rat hearts. Toxicol. Appl. Pharmacol. 107: 535-544.
55. Spinale FG. 2002. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ. Res. 90: 520-530.
56. Stawowy P, Blaschke F, Pfautsch P, Goetze S, Lippek F, Wollert-Wulf B, Fleck E, Graf K. 2002. Increased myocardial expression of osteopontin in patients with advanced heart failure. Eur. J. Heart Fail. 4: 139-146.
57. Suzuki J, Tsubone H, Sugano S. 1991. Characteristics of electrocardiographic changes with some representative antiarrhythmic drugs in adult rats. J. Vet. Med. Sci. 53: 779-787.
58. Szalay G, Sauter M, Haberland M, Zuegel U, Steinmeyer A, Kandolf R, Klingel K. 2009. Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ. Res. 104: 851-859.
59. Takeshita K, Hayashi M, Iino S, Kondo T, Inden Y, Iwase M, Kojima T, Hirai M, Ito M, Loskutoff DJ, Saito H, Murohara T, Yamamoto K. 2004. Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am. J. Pathol. 164: 449-456.
60. Toennes SW, Schmidt K, Fandiño AS, Kauert GF. 2002. A fatal human intoxication with the herbicide allyl alcohol (2-propen-1-ol). J. Anal. Toxicol. 26: 55-57.
61. Tonomura Y, Mori Y, Torii M, Uehara T. 2009. Evaluation of the usefulness of biomarkers for cardiac and skeletal myotoxicity in rats. Toxicology 266: 48-54.
62. Uehara T, Kiyosawa N, Hirode M, Omura K, Shimizu T, Ono A, Mizukawa Y, Miyagishima T, Nagao T, Urushidani T. 2008. Gene expression profiling of methapyrilene-induced hepatotoxicity in rat. J. Toxicol. Sci. 33: 37-50.
63. Yang A, Trajkovic D, Illanes O, Ramiro-Ibáñez F. 2007. Clinicopathological and tissue indicators of para-aminophenol nephrotoxicity in Sprague-Dawley rats. Toxicol. Pathol. 35: 521-532.
64. Zahradka P. 2009. Novel Role for Osteopontin in Cardiac Fibrosis. Circ. Res. 102: 270-272.
65. Zaman AK, French CJ, Schneider DJ, Sobel BE. 2009. A profibrotic effect of plasminogen activator inhibitor type-1 (PAI-1) in the heart. Exp. Biol. Med. (Maywood) 234: 246-254.